Immunitybio, Inc.

2015 Equity Incentive Plan 2015 Share Repurchase Plan Board of Directors-approved share repurchase program 2025 Plan ImmunityBio, Inc.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

We may also seek to sell additional equity through one or more follow-on offerings, or in separate financings, or obtain incremental subordinated debt in compliance with our existing revenue interest liability.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Recent Accounting Pronouncements Application of New or Revised Accounting Standards Adopted In November 2024, the FASB issued ASU 2024-04, Debt Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments , which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

and Subsidiaries Notes to Unaudited Condensed Consolidated Financial Statements (Continued) As of June 30, 2026 and December 31, 2025, all contractual maturities of marketable debt securities were 12 months or less.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

During the six months ended June 30, 2026 and 2025, we evaluated our marketable debt securities and determined that unrealized losses resulted from changes in interest rates and market spreads after purchase.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

In addition, ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease, in addition to the currently recognized CIS with or without papillary disease.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

With commercial authorization now in place in the UK, we re actively evaluating our go-to-market strategy for this important initial global market.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

To that end, we ve begun global expansion of key clinical trials, including those for BCG-na ve NMIBC and second-line lung cancer.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

FDA, including with respect to the previously reported RTF letter received by the Company and potential implications thereof, potential next steps, decisions and timelines related to the Company s regulatory submissions and strategy, participation by urology practices in ImmunityBio s rBCG EAP, the expectation that the rBCG EAP will enable ImmunityBio to reliably bring an alternative source of BCG to patients in the U.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as anticipates, believes, continues, goal, could, estimates, scheduled, expects, intends, may, plans, potential, predicts, indicate, projects, is, seeks, should, will, strategy, and variations of such words or similar expressions.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The decrease was due to lower costs related to litigation settlements and commercial consulting activities.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The decrease was primarily driven by lower costs related to litigation settlements and commercial consulting activities, partially offset by higher stock-based compensation expense, recruiting and training expenses, salaries, benefits and commissions, and travel expenses due to growing sales and marketing activities.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, as well as that associated with regulatory agencies outside of the U.

SEC original ↗Immunitybio, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 64 Item 1A.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Further, because of the risk and uncertainties associated with the global commercialization of our approved product and our other product candidates, we may need additional funds to meet our needs sooner than planned.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Litigation From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations.

SEC original ↗Immunitybio, Inc. — 10-Q Quarterly report10-QAug 4, 2026